ASGO2023

Cervical cancer web-based clinical decision support tool

Home Back
ASGO2023
More Information View All
  • Preferred regimens
    For patients not previously treated with chemotherapy
    1) Pembrolizumab+Paclitaxel+Cisplatin(Carboplatin)±Bevacizumab, if all the drugs are available and PD-L1(+)
    2) Paclitaxel+Cisplatin(Carboplatin)+Bevacizumab
  • Recurrence after first-line platinum-based chemotherapy
    - Cemiplimab, if the drug is available and PD-L1(+)
    - Pembrolizumab, if the drug is available and PD-L1(+)
    - Tisotumab vedotin-tftv

Copyright 2023. Asian Society of Gynecologic Oncology